Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Prime Medicine, Inc. (PRME)

Prime Medicine Q1 2026 net loss narrows to $49.1 million; revenue falls

Mixed Impact 3 of 5 earnings Written later

Prime Medicine reported a first-quarter 2026 net loss of $49.1 million, down from $51.9 million a year earlier, and loss per share of $0.28 versus $0.40. Collaboration revenue fell to $856,000 from $1.454 million, and G&A expenses rose on arbitration-related legal costs. Cash and investments were $149.2 million at March 31, 2026, which the company says funds operations into 2027.

Key points

  • Net loss $49.1 million vs. $51.9 million in Q1 2025; loss per share $0.28 vs. $0.40
  • Collaboration revenue $856,000 vs. $1.454 million in Q1 2025
  • R&D expenses $34.1 million vs. $40.6 million; G&A expenses $17.4 million vs. $13.3 million, driven by arbitration-related legal expenses
  • Cash, cash equivalents, investments and restricted cash $149.2 million at March 31, 2026, vs. $191.4 million at December 31, 2025

The filing

CompanyPrime Medicine, Inc. (PRME)
Form8-K, current report
Filed with the SECMay 7, 2026, 8:10 AM ET
Accession number0001628280-26-031719

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.